Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Deductibles and Coinsurance | 37 | 2023 | 316 | 6.520 |
Why?
|
Drug Costs | 33 | 2021 | 1105 | 2.800 |
Why?
|
Health Maintenance Organizations | 25 | 2013 | 642 | 2.660 |
Why?
|
Drug Utilization | 35 | 2020 | 1183 | 2.220 |
Why?
|
Cost Sharing | 15 | 2024 | 407 | 2.180 |
Why?
|
Diabetes Mellitus | 30 | 2024 | 5751 | 2.050 |
Why?
|
Drug Prescriptions | 37 | 2021 | 1637 | 2.030 |
Why?
|
Patient Compliance | 17 | 2017 | 2684 | 1.980 |
Why?
|
Inappropriate Prescribing | 4 | 2021 | 202 | 1.980 |
Why?
|
Insurance, Health | 31 | 2022 | 2494 | 1.920 |
Why?
|
Drugs, Essential | 9 | 2020 | 73 | 1.790 |
Why?
|
Health Expenditures | 26 | 2022 | 2348 | 1.780 |
Why?
|
Insurance Coverage | 23 | 2020 | 1901 | 1.600 |
Why?
|
Financing, Personal | 13 | 2020 | 308 | 1.570 |
Why?
|
Hypoglycemic Agents | 15 | 2024 | 2872 | 1.470 |
Why?
|
Medicare Part D | 14 | 2021 | 328 | 1.380 |
Why?
|
Health Services Accessibility | 23 | 2022 | 5137 | 1.370 |
Why?
|
Health Policy | 26 | 2020 | 2661 | 1.350 |
Why?
|
Health Benefit Plans, Employee | 4 | 2017 | 332 | 1.300 |
Why?
|
Respiratory Tract Infections | 10 | 2021 | 961 | 1.230 |
Why?
|
Community Health Services | 5 | 2020 | 650 | 1.210 |
Why?
|
Diabetes Complications | 6 | 2024 | 1359 | 1.180 |
Why?
|
Insurance, Pharmaceutical Services | 17 | 2011 | 336 | 1.150 |
Why?
|
Developing Countries | 15 | 2022 | 2815 | 1.140 |
Why?
|
Medicaid | 34 | 2021 | 2736 | 1.090 |
Why?
|
Poverty | 17 | 2022 | 2660 | 1.070 |
Why?
|
National Health Programs | 6 | 2019 | 445 | 1.010 |
Why?
|
Workload | 2 | 2021 | 850 | 1.010 |
Why?
|
Drug Therapy | 11 | 2014 | 497 | 0.990 |
Why?
|
Medication Adherence | 14 | 2021 | 2063 | 0.920 |
Why?
|
Benzodiazepines | 10 | 2015 | 1101 | 0.910 |
Why?
|
Antihypertensive Agents | 10 | 2019 | 2046 | 0.890 |
Why?
|
Pharmacies | 6 | 2019 | 150 | 0.890 |
Why?
|
Pharmaceutical Preparations | 6 | 2013 | 1071 | 0.870 |
Why?
|
China | 12 | 2023 | 2248 | 0.860 |
Why?
|
Healthcare Disparities | 8 | 2018 | 3158 | 0.850 |
Why?
|
Carbapenems | 1 | 2023 | 118 | 0.850 |
Why?
|
Medical Savings Accounts | 3 | 2022 | 32 | 0.850 |
Why?
|
Gastric Bypass | 8 | 2024 | 812 | 0.830 |
Why?
|
Blood Glucose Self-Monitoring | 5 | 2019 | 434 | 0.810 |
Why?
|
Medicare | 24 | 2022 | 6566 | 0.750 |
Why?
|
Diabetic Ketoacidosis | 1 | 2024 | 245 | 0.750 |
Why?
|
Bronchitis | 1 | 2021 | 201 | 0.740 |
Why?
|
Patient Acceptance of Health Care | 12 | 2020 | 3022 | 0.730 |
Why?
|
Contraception | 2 | 2021 | 359 | 0.720 |
Why?
|
Health Personnel | 5 | 2022 | 3218 | 0.710 |
Why?
|
Emergency Service, Hospital | 15 | 2021 | 7659 | 0.710 |
Why?
|
Speech Recognition Software | 2 | 2010 | 72 | 0.700 |
Why?
|
Drug Utilization Review | 10 | 2015 | 245 | 0.690 |
Why?
|
Middle Aged | 131 | 2024 | 213383 | 0.690 |
Why?
|
Humans | 291 | 2024 | 744343 | 0.690 |
Why?
|
Treatment Refusal | 7 | 2013 | 421 | 0.670 |
Why?
|
Health Care Costs | 15 | 2024 | 3209 | 0.670 |
Why?
|
Adult | 123 | 2023 | 214055 | 0.660 |
Why?
|
Ambulatory Care | 5 | 2017 | 2708 | 0.650 |
Why?
|
Frail Elderly | 2 | 2020 | 693 | 0.650 |
Why?
|
Telephone | 4 | 2014 | 617 | 0.650 |
Why?
|
Delayed Diagnosis | 2 | 2019 | 441 | 0.640 |
Why?
|
Obesity, Morbid | 7 | 2024 | 1213 | 0.630 |
Why?
|
Diabetes Mellitus, Type 2 | 14 | 2024 | 11725 | 0.630 |
Why?
|
Female | 168 | 2024 | 380194 | 0.620 |
Why?
|
Bipolar Disorder | 10 | 2022 | 5027 | 0.610 |
Why?
|
Appointments and Schedules | 4 | 2020 | 417 | 0.610 |
Why?
|
Family Characteristics | 6 | 2016 | 1000 | 0.610 |
Why?
|
Early Detection of Cancer | 6 | 2020 | 3086 | 0.600 |
Why?
|
Mammography | 5 | 2022 | 2476 | 0.600 |
Why?
|
Anti-Bacterial Agents | 11 | 2023 | 7181 | 0.580 |
Why?
|
Guideline Adherence | 7 | 2014 | 2266 | 0.570 |
Why?
|
Reimbursement Mechanisms | 11 | 2021 | 670 | 0.560 |
Why?
|
United States | 89 | 2022 | 69872 | 0.560 |
Why?
|
Patient Readmission | 7 | 2020 | 3114 | 0.540 |
Why?
|
Program Evaluation | 8 | 2020 | 2488 | 0.530 |
Why?
|
Male | 143 | 2024 | 350118 | 0.530 |
Why?
|
Nonprescription Drugs | 1 | 2016 | 116 | 0.530 |
Why?
|
Hypolipidemic Agents | 3 | 2017 | 604 | 0.530 |
Why?
|
Health Care Reform | 6 | 2016 | 1261 | 0.530 |
Why?
|
Fees, Pharmaceutical | 6 | 2011 | 64 | 0.520 |
Why?
|
Breast Neoplasms | 15 | 2022 | 20822 | 0.520 |
Why?
|
Chronic Disease | 14 | 2021 | 9146 | 0.520 |
Why?
|
Diarrhea | 4 | 2014 | 1348 | 0.520 |
Why?
|
Medical Indigency | 4 | 2011 | 64 | 0.520 |
Why?
|
Health Services Research | 11 | 2015 | 1836 | 0.520 |
Why?
|
Length of Stay | 8 | 2017 | 6309 | 0.510 |
Why?
|
Mass Screening | 6 | 2017 | 5255 | 0.500 |
Why?
|
Antidepressive Agents | 9 | 2017 | 2838 | 0.490 |
Why?
|
Aged | 91 | 2022 | 163280 | 0.490 |
Why?
|
Anti-Anxiety Agents | 3 | 2007 | 390 | 0.480 |
Why?
|
Quality Assurance, Health Care | 6 | 2018 | 2212 | 0.470 |
Why?
|
Longitudinal Studies | 23 | 2021 | 13989 | 0.470 |
Why?
|
Malaria | 3 | 2014 | 1239 | 0.470 |
Why?
|
Vulnerable Populations | 2 | 2019 | 687 | 0.470 |
Why?
|
Continuity of Patient Care | 3 | 2017 | 1049 | 0.470 |
Why?
|
Medication Therapy Management | 1 | 2014 | 127 | 0.460 |
Why?
|
Gastrectomy | 7 | 2024 | 663 | 0.450 |
Why?
|
Adolescent | 56 | 2021 | 85781 | 0.450 |
Why?
|
Cluster Analysis | 5 | 2014 | 2715 | 0.440 |
Why?
|
Private Practice | 2 | 2004 | 154 | 0.440 |
Why?
|
Patient Protection and Affordable Care Act | 8 | 2022 | 1209 | 0.440 |
Why?
|
Young Adult | 40 | 2021 | 56430 | 0.440 |
Why?
|
Preventive Medicine | 1 | 2015 | 264 | 0.440 |
Why?
|
Hospitalization | 14 | 2021 | 10262 | 0.440 |
Why?
|
Postnatal Care | 5 | 2016 | 236 | 0.440 |
Why?
|
Patient Admission | 4 | 2017 | 1380 | 0.440 |
Why?
|
Socioeconomic Factors | 22 | 2017 | 7785 | 0.430 |
Why?
|
Regression Analysis | 10 | 2016 | 6459 | 0.420 |
Why?
|
Gastrointestinal Diseases | 4 | 2011 | 1170 | 0.420 |
Why?
|
Sexual Behavior | 2 | 2019 | 2057 | 0.410 |
Why?
|
Suicide, Attempted | 1 | 2020 | 1221 | 0.410 |
Why?
|
Insurance Claim Review | 13 | 2021 | 720 | 0.400 |
Why?
|
Quality Control | 1 | 2014 | 841 | 0.400 |
Why?
|
Heart Diseases | 2 | 2024 | 2788 | 0.400 |
Why?
|
Health Care Surveys | 12 | 2013 | 2453 | 0.400 |
Why?
|
Cross-Sectional Studies | 25 | 2021 | 25043 | 0.390 |
Why?
|
Cost of Illness | 5 | 2019 | 1859 | 0.390 |
Why?
|
Quality of Health Care | 15 | 2018 | 4371 | 0.390 |
Why?
|
Acute Disease | 5 | 2016 | 7149 | 0.390 |
Why?
|
Prescription Fees | 6 | 2014 | 146 | 0.380 |
Why?
|
Massachusetts | 22 | 2016 | 8663 | 0.380 |
Why?
|
Public Sector | 3 | 2011 | 265 | 0.380 |
Why?
|
Cohort Studies | 34 | 2024 | 40561 | 0.370 |
Why?
|
Primary Health Care | 9 | 2023 | 4558 | 0.360 |
Why?
|
Legislation, Drug | 4 | 2007 | 206 | 0.360 |
Why?
|
Commerce | 5 | 2020 | 592 | 0.350 |
Why?
|
Income | 7 | 2021 | 1913 | 0.350 |
Why?
|
Social Class | 4 | 2015 | 1999 | 0.350 |
Why?
|
Colorectal Neoplasms | 4 | 2016 | 6773 | 0.350 |
Why?
|
Philippines | 4 | 2020 | 86 | 0.340 |
Why?
|
Evaluation Studies as Topic | 1 | 2011 | 1681 | 0.340 |
Why?
|
Health Surveys | 7 | 2013 | 4037 | 0.330 |
Why?
|
Data Collection | 9 | 2010 | 3341 | 0.330 |
Why?
|
Physicians | 6 | 2021 | 4567 | 0.330 |
Why?
|
Retrospective Studies | 42 | 2024 | 77449 | 0.330 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2017 | 1873 | 0.330 |
Why?
|
Confidence Intervals | 5 | 2013 | 2971 | 0.330 |
Why?
|
Community-Institutional Relations | 1 | 2010 | 204 | 0.320 |
Why?
|
Drugs, Generic | 4 | 2019 | 421 | 0.320 |
Why?
|
Policy Making | 3 | 2011 | 554 | 0.310 |
Why?
|
Insurance, Hospitalization | 1 | 2007 | 30 | 0.300 |
Why?
|
Midwifery | 1 | 2009 | 132 | 0.300 |
Why?
|
Antipsychotic Agents | 8 | 2022 | 3057 | 0.290 |
Why?
|
Drug Industry | 8 | 2018 | 746 | 0.290 |
Why?
|
Patient Discharge | 6 | 2020 | 3313 | 0.290 |
Why?
|
Interviews as Topic | 10 | 2018 | 2539 | 0.290 |
Why?
|
Brazil | 6 | 2020 | 1270 | 0.290 |
Why?
|
Insurance Benefits | 3 | 2015 | 183 | 0.290 |
Why?
|
Anti-Retroviral Agents | 3 | 2013 | 1715 | 0.280 |
Why?
|
Hypertension | 9 | 2020 | 8480 | 0.280 |
Why?
|
Electronic Health Records | 3 | 2020 | 4468 | 0.270 |
Why?
|
Mental Health | 1 | 2020 | 3019 | 0.270 |
Why?
|
Respiratory Tract Diseases | 1 | 2011 | 722 | 0.270 |
Why?
|
Costs and Cost Analysis | 7 | 2021 | 1681 | 0.270 |
Why?
|
Aftercare | 2 | 2020 | 866 | 0.270 |
Why?
|
Health Services Needs and Demand | 2 | 2013 | 1411 | 0.270 |
Why?
|
Delivery of Health Care | 10 | 2019 | 5319 | 0.260 |
Why?
|
Models, Statistical | 2 | 2011 | 5102 | 0.260 |
Why?
|
Nicaragua | 2 | 2015 | 27 | 0.260 |
Why?
|
Economic Recession | 3 | 2014 | 78 | 0.260 |
Why?
|
Prenatal Care | 2 | 2011 | 1092 | 0.260 |
Why?
|
Multivariate Analysis | 12 | 2015 | 12245 | 0.260 |
Why?
|
Honduras | 2 | 2015 | 36 | 0.260 |
Why?
|
Antineoplastic Agents | 7 | 2021 | 13695 | 0.260 |
Why?
|
Residence Characteristics | 5 | 2018 | 2050 | 0.250 |
Why?
|
Prescriptions | 2 | 2008 | 387 | 0.250 |
Why?
|
Uganda | 6 | 2014 | 1243 | 0.250 |
Why?
|
Cost Control | 11 | 2014 | 624 | 0.250 |
Why?
|
Managed Care Programs | 3 | 2008 | 950 | 0.250 |
Why?
|
Severity of Illness Index | 4 | 2011 | 15540 | 0.250 |
Why?
|
New Jersey | 9 | 2007 | 290 | 0.240 |
Why?
|
Logistic Models | 14 | 2020 | 13408 | 0.240 |
Why?
|
Guatemala | 2 | 2015 | 142 | 0.240 |
Why?
|
Occult Blood | 3 | 2016 | 176 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2014 | 2020 | 0.240 |
Why?
|
Obstetrics and Gynecology Department, Hospital | 2 | 2003 | 43 | 0.240 |
Why?
|
Jaundice, Neonatal | 1 | 2004 | 71 | 0.230 |
Why?
|
Time Factors | 17 | 2019 | 40075 | 0.230 |
Why?
|
Penicillins | 2 | 2023 | 380 | 0.230 |
Why?
|
Age Factors | 12 | 2019 | 18370 | 0.230 |
Why?
|
Africa, Eastern | 4 | 2013 | 71 | 0.230 |
Why?
|
Hospitals, District | 1 | 2004 | 106 | 0.220 |
Why?
|
Eligibility Determination | 4 | 2020 | 403 | 0.220 |
Why?
|
Drug Approval | 3 | 2021 | 742 | 0.220 |
Why?
|
Hospital Costs | 2 | 2015 | 985 | 0.220 |
Why?
|
Child, Preschool | 26 | 2021 | 41006 | 0.220 |
Why?
|
Survivors | 3 | 2022 | 2291 | 0.220 |
Why?
|
Reye Syndrome | 2 | 2000 | 28 | 0.220 |
Why?
|
Analgesics, Opioid | 6 | 2016 | 3674 | 0.220 |
Why?
|
Aged, 80 and over | 25 | 2021 | 57776 | 0.220 |
Why?
|
Fee-for-Service Plans | 4 | 2017 | 694 | 0.220 |
Why?
|
Child | 33 | 2021 | 77709 | 0.220 |
Why?
|
Research Design | 7 | 2014 | 5987 | 0.220 |
Why?
|
Anti-HIV Agents | 4 | 2014 | 4256 | 0.220 |
Why?
|
State Health Plans | 7 | 2013 | 216 | 0.220 |
Why?
|
Tanzania | 2 | 2017 | 1346 | 0.210 |
Why?
|
Community Pharmacy Services | 2 | 2019 | 46 | 0.210 |
Why?
|
Gatekeeping | 4 | 2010 | 45 | 0.210 |
Why?
|
Infant | 22 | 2020 | 35136 | 0.210 |
Why?
|
Helicobacter pylori | 2 | 2005 | 382 | 0.210 |
Why?
|
Health Status Disparities | 2 | 2016 | 1797 | 0.210 |
Why?
|
Private Sector | 2 | 2016 | 392 | 0.210 |
Why?
|
Helicobacter Infections | 2 | 2005 | 386 | 0.210 |
Why?
|
Thiazolidinediones | 2 | 2015 | 476 | 0.210 |
Why?
|
Pharmaceutical Services | 3 | 2008 | 140 | 0.210 |
Why?
|
World Health Organization | 6 | 2016 | 1318 | 0.200 |
Why?
|
Delivery, Obstetric | 1 | 2009 | 906 | 0.200 |
Why?
|
Oxycodone | 3 | 2015 | 153 | 0.200 |
Why?
|
Psychotropic Drugs | 5 | 2015 | 894 | 0.190 |
Why?
|
HIV Infections | 7 | 2014 | 16718 | 0.190 |
Why?
|
Disabled Persons | 6 | 2021 | 1212 | 0.190 |
Why?
|
Education, Medical, Continuing | 4 | 2004 | 840 | 0.190 |
Why?
|
Nebulizers and Vaporizers | 1 | 2021 | 139 | 0.190 |
Why?
|
Breast Feeding | 3 | 2004 | 1338 | 0.190 |
Why?
|
Kenya | 7 | 2014 | 685 | 0.190 |
Why?
|
Insulin | 4 | 2021 | 6580 | 0.180 |
Why?
|
New York | 5 | 2007 | 886 | 0.180 |
Why?
|
Product Surveillance, Postmarketing | 3 | 1994 | 430 | 0.180 |
Why?
|
New England | 4 | 2018 | 1022 | 0.180 |
Why?
|
Hip Fractures | 2 | 2007 | 955 | 0.180 |
Why?
|
Hernia, Hiatal | 1 | 2020 | 79 | 0.180 |
Why?
|
Negotiating | 1 | 2021 | 133 | 0.180 |
Why?
|
Case Management | 1 | 2021 | 286 | 0.170 |
Why?
|
Asthma | 4 | 2023 | 6011 | 0.170 |
Why?
|
Sex Factors | 9 | 2014 | 10397 | 0.170 |
Why?
|
Sampling Studies | 4 | 2010 | 623 | 0.170 |
Why?
|
Patient Education as Topic | 2 | 2008 | 2278 | 0.170 |
Why?
|
Neoplasms | 7 | 2021 | 21683 | 0.170 |
Why?
|
Depressive Disorder | 3 | 2007 | 3748 | 0.170 |
Why?
|
Choice Behavior | 2 | 2017 | 803 | 0.170 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2020 | 397 | 0.170 |
Why?
|
Models, Theoretical | 2 | 2010 | 3589 | 0.170 |
Why?
|
Thailand | 5 | 2020 | 296 | 0.170 |
Why?
|
Pharmacy | 1 | 2020 | 91 | 0.170 |
Why?
|
Polypharmacy | 2 | 2014 | 294 | 0.160 |
Why?
|
Health Promotion | 4 | 2018 | 2205 | 0.160 |
Why?
|
Attitude of Health Personnel | 5 | 2018 | 3843 | 0.160 |
Why?
|
Risk Factors | 18 | 2021 | 72290 | 0.160 |
Why?
|
Anti-Ulcer Agents | 3 | 2010 | 119 | 0.160 |
Why?
|
Infant, Newborn | 14 | 2020 | 25625 | 0.150 |
Why?
|
Health Services for the Aged | 1 | 2020 | 269 | 0.150 |
Why?
|
Antidiarrheals | 2 | 1996 | 45 | 0.150 |
Why?
|
Reimbursement, Incentive | 2 | 2014 | 540 | 0.150 |
Why?
|
Family Health | 3 | 2012 | 1282 | 0.150 |
Why?
|
Blindness | 6 | 1996 | 617 | 0.150 |
Why?
|
Contraceptive Agents | 1 | 2019 | 151 | 0.150 |
Why?
|
Malaysia | 3 | 2023 | 92 | 0.150 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2007 | 3923 | 0.150 |
Why?
|
Colonoscopy | 3 | 2016 | 1367 | 0.150 |
Why?
|
Drug and Narcotic Control | 3 | 2014 | 146 | 0.150 |
Why?
|
Medical Audit | 3 | 2009 | 467 | 0.150 |
Why?
|
Anticonvulsants | 4 | 2011 | 1916 | 0.140 |
Why?
|
Health Services | 4 | 2014 | 758 | 0.140 |
Why?
|
Education, Pharmacy | 1 | 1996 | 35 | 0.140 |
Why?
|
Self Care | 4 | 2015 | 786 | 0.140 |
Why?
|
Anti-Asthmatic Agents | 1 | 2021 | 536 | 0.140 |
Why?
|
Condoms | 1 | 2019 | 323 | 0.140 |
Why?
|
Xerophthalmia | 1 | 1996 | 18 | 0.140 |
Why?
|
Marketing | 2 | 2009 | 212 | 0.140 |
Why?
|
Nursing Homes | 3 | 2020 | 1036 | 0.140 |
Why?
|
Biopsy | 2 | 2019 | 6756 | 0.140 |
Why?
|
Medical Assistance | 1 | 2016 | 104 | 0.140 |
Why?
|
Pain | 3 | 2015 | 4986 | 0.140 |
Why?
|
Linear Models | 4 | 2017 | 5952 | 0.140 |
Why?
|
Financing, Government | 1 | 2020 | 468 | 0.140 |
Why?
|
Weight Loss | 3 | 2024 | 2622 | 0.140 |
Why?
|
Taiwan | 2 | 2015 | 496 | 0.140 |
Why?
|
Warfarin | 4 | 2008 | 1496 | 0.130 |
Why?
|
Public-Private Sector Partnerships | 1 | 2016 | 121 | 0.130 |
Why?
|
New Hampshire | 7 | 2010 | 172 | 0.130 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2015 | 38 | 0.130 |
Why?
|
Data Interpretation, Statistical | 4 | 2014 | 2716 | 0.130 |
Why?
|
Home Infusion Therapy | 1 | 1995 | 19 | 0.130 |
Why?
|
Family Practice | 3 | 2013 | 516 | 0.130 |
Why?
|
Government Regulation | 1 | 2019 | 522 | 0.130 |
Why?
|
Health Education | 5 | 2008 | 1056 | 0.130 |
Why?
|
New York City | 1 | 2017 | 710 | 0.130 |
Why?
|
Jordan | 1 | 2014 | 74 | 0.120 |
Why?
|
Schizophrenia | 6 | 2015 | 6882 | 0.120 |
Why?
|
Administration, Oral | 3 | 2021 | 3913 | 0.120 |
Why?
|
Africa | 3 | 2011 | 673 | 0.120 |
Why?
|
Conservation of Natural Resources | 1 | 2016 | 204 | 0.120 |
Why?
|
Medically Uninsured | 1 | 2020 | 853 | 0.120 |
Why?
|
Cooperative Behavior | 1 | 2001 | 1504 | 0.120 |
Why?
|
Diagnostic Imaging | 2 | 2019 | 3507 | 0.120 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2017 | 451 | 0.120 |
Why?
|
Mental Disorders | 3 | 2004 | 6600 | 0.120 |
Why?
|
Tolmetin | 1 | 1993 | 23 | 0.120 |
Why?
|
Prescription Drugs | 2 | 2013 | 595 | 0.120 |
Why?
|
Follow-Up Studies | 11 | 2019 | 39050 | 0.120 |
Why?
|
Patient Transfer | 2 | 2017 | 761 | 0.120 |
Why?
|
BRCA1 Protein | 1 | 2020 | 1149 | 0.120 |
Why?
|
Gastroplasty | 1 | 2015 | 142 | 0.120 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7279 | 0.120 |
Why?
|
Ghana | 1 | 2014 | 286 | 0.110 |
Why?
|
Odds Ratio | 5 | 2021 | 9849 | 0.110 |
Why?
|
Organizational Policy | 3 | 2011 | 429 | 0.110 |
Why?
|
Community Health Planning | 1 | 2014 | 165 | 0.110 |
Why?
|
Dyspepsia | 2 | 2005 | 115 | 0.110 |
Why?
|
Diabetic Angiopathies | 1 | 2018 | 818 | 0.110 |
Why?
|
Outpatients | 1 | 2021 | 1486 | 0.110 |
Why?
|
Competitive Medical Plans | 1 | 2013 | 24 | 0.110 |
Why?
|
Blood Glucose | 2 | 2019 | 6256 | 0.110 |
Why?
|
Infection Control | 1 | 2000 | 966 | 0.110 |
Why?
|
Counseling | 1 | 2021 | 1523 | 0.110 |
Why?
|
Back Pain | 1 | 2017 | 545 | 0.110 |
Why?
|
Anti-Infective Agents, Local | 2 | 2005 | 250 | 0.110 |
Why?
|
Sexually Transmitted Diseases | 1 | 2018 | 624 | 0.110 |
Why?
|
Factor VIII | 1 | 1995 | 347 | 0.110 |
Why?
|
Norway | 1 | 2013 | 448 | 0.100 |
Why?
|
Hospitals, Public | 1 | 2013 | 207 | 0.100 |
Why?
|
Glucose Intolerance | 1 | 2016 | 577 | 0.100 |
Why?
|
Prediabetic State | 1 | 2017 | 499 | 0.100 |
Why?
|
Health Status | 4 | 2015 | 4034 | 0.100 |
Why?
|
Treatment Outcome | 10 | 2024 | 63114 | 0.100 |
Why?
|
Utilization Review | 1 | 2013 | 392 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 9959 | 0.100 |
Why?
|
Risk Management | 1 | 2015 | 571 | 0.100 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 1519 | 0.100 |
Why?
|
Hemophilia A | 1 | 1995 | 351 | 0.100 |
Why?
|
Anxiety | 1 | 2006 | 4297 | 0.100 |
Why?
|
Psychometrics | 2 | 2008 | 3002 | 0.100 |
Why?
|
Prepaid Health Plans | 1 | 2010 | 10 | 0.100 |
Why?
|
Suicidal Ideation | 1 | 2020 | 1248 | 0.100 |
Why?
|
Comorbidity | 5 | 2014 | 10388 | 0.100 |
Why?
|
Hospitals, Maternity | 1 | 2011 | 42 | 0.100 |
Why?
|
Myocardial Infarction | 4 | 2002 | 11727 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 933 | 0.100 |
Why?
|
Community Mental Health Centers | 1 | 2011 | 102 | 0.100 |
Why?
|
Hospitalists | 2 | 2007 | 305 | 0.090 |
Why?
|
Histamine H2 Antagonists | 2 | 2005 | 165 | 0.090 |
Why?
|
Bariatric Surgery | 1 | 2020 | 952 | 0.090 |
Why?
|
Pharmacoepidemiology | 3 | 2015 | 323 | 0.090 |
Why?
|
Mass Media | 4 | 2003 | 305 | 0.090 |
Why?
|
Decision Making, Organizational | 1 | 2010 | 139 | 0.090 |
Why?
|
International Agencies | 1 | 1991 | 240 | 0.090 |
Why?
|
Telemedicine | 2 | 2019 | 2872 | 0.090 |
Why?
|
Antimanic Agents | 1 | 2014 | 522 | 0.090 |
Why?
|
Clinical Competence | 2 | 2006 | 4687 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 2 | 2014 | 783 | 0.090 |
Why?
|
Hypnotics and Sedatives | 3 | 2015 | 1162 | 0.090 |
Why?
|
Postpartum Period | 1 | 2016 | 1086 | 0.090 |
Why?
|
Headache | 1 | 2017 | 1226 | 0.090 |
Why?
|
Maine | 4 | 2011 | 139 | 0.090 |
Why?
|
Organizations, Nonprofit | 1 | 2010 | 104 | 0.090 |
Why?
|
Health Services Misuse | 4 | 2016 | 243 | 0.090 |
Why?
|
Hepatitis C | 1 | 2019 | 1591 | 0.090 |
Why?
|
Pregnancy | 6 | 2021 | 29144 | 0.090 |
Why?
|
Patient Satisfaction | 3 | 2017 | 3396 | 0.080 |
Why?
|
Pediatrics | 3 | 2010 | 3475 | 0.080 |
Why?
|
Body Mass Index | 4 | 2021 | 12720 | 0.080 |
Why?
|
Analgesia | 1 | 1993 | 461 | 0.080 |
Why?
|
Low Back Pain | 1 | 2017 | 956 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2017 | 941 | 0.080 |
Why?
|
Health Behavior | 1 | 2000 | 2636 | 0.080 |
Why?
|
Propensity Score | 2 | 2015 | 1781 | 0.080 |
Why?
|
Terminal Care | 1 | 2020 | 1694 | 0.080 |
Why?
|
Indonesia | 2 | 2020 | 119 | 0.080 |
Why?
|
Databases, Factual | 6 | 2020 | 7729 | 0.080 |
Why?
|
Pregnancy Outcome | 1 | 2019 | 2795 | 0.080 |
Why?
|
Hyperlipidemias | 2 | 2011 | 789 | 0.080 |
Why?
|
Quality Indicators, Health Care | 4 | 2018 | 1831 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2018 | 11031 | 0.080 |
Why?
|
Evidence-Based Practice | 1 | 2013 | 500 | 0.080 |
Why?
|
Age Distribution | 4 | 2020 | 2902 | 0.080 |
Why?
|
Observation | 2 | 2008 | 312 | 0.080 |
Why?
|
Sample Size | 1 | 2011 | 845 | 0.080 |
Why?
|
Electronic Prescribing | 1 | 2009 | 121 | 0.080 |
Why?
|
Cardiovascular Diseases | 5 | 2022 | 15165 | 0.080 |
Why?
|
Health Facilities | 2 | 2010 | 573 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2018 | 1524 | 0.080 |
Why?
|
Anti-Infective Agents | 2 | 2010 | 972 | 0.080 |
Why?
|
Aromatase Inhibitors | 1 | 2011 | 491 | 0.080 |
Why?
|
Anticoagulants | 3 | 2008 | 4599 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2017 | 3047 | 0.080 |
Why?
|
Physicians, Primary Care | 1 | 2014 | 591 | 0.080 |
Why?
|
Prevalence | 10 | 2021 | 15226 | 0.080 |
Why?
|
Health Literacy | 1 | 2013 | 414 | 0.070 |
Why?
|
Equipment Failure | 1 | 2010 | 578 | 0.070 |
Why?
|
Substance-Related Disorders | 1 | 2004 | 4258 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2019 | 2987 | 0.070 |
Why?
|
Group Practice | 1 | 2008 | 149 | 0.070 |
Why?
|
Peru | 1 | 2010 | 881 | 0.070 |
Why?
|
Health Resources | 1 | 2013 | 911 | 0.070 |
Why?
|
Hospitals | 4 | 2020 | 3952 | 0.070 |
Why?
|
Corneal Opacity | 2 | 1986 | 60 | 0.070 |
Why?
|
Pilot Projects | 4 | 2020 | 8324 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 15076 | 0.070 |
Why?
|
Tamoxifen | 1 | 2011 | 981 | 0.070 |
Why?
|
Medical Staff, Hospital | 2 | 2006 | 603 | 0.070 |
Why?
|
Analgesics | 1 | 1993 | 1040 | 0.070 |
Why?
|
Diabetes, Gestational | 1 | 2016 | 1184 | 0.070 |
Why?
|
Case-Control Studies | 5 | 2023 | 21746 | 0.070 |
Why?
|
Reproducibility of Results | 6 | 2015 | 19905 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 1993 | 2282 | 0.070 |
Why?
|
Indiana | 3 | 2011 | 92 | 0.070 |
Why?
|
International Cooperation | 1 | 1992 | 1420 | 0.070 |
Why?
|
International Classification of Diseases | 2 | 2008 | 867 | 0.070 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2006 | 103 | 0.070 |
Why?
|
Television | 2 | 2006 | 409 | 0.070 |
Why?
|
Korea | 1 | 2005 | 99 | 0.070 |
Why?
|
Physician Assistants | 1 | 2008 | 193 | 0.070 |
Why?
|
Poisson Distribution | 1 | 2007 | 513 | 0.070 |
Why?
|
Preventive Health Services | 1 | 2010 | 575 | 0.070 |
Why?
|
Remote Consultation | 1 | 2008 | 238 | 0.070 |
Why?
|
Michigan | 3 | 2011 | 350 | 0.060 |
Why?
|
Quality Improvement | 3 | 2017 | 3749 | 0.060 |
Why?
|
Dextropropoxyphene | 2 | 2015 | 26 | 0.060 |
Why?
|
Self Administration | 1 | 2006 | 385 | 0.060 |
Why?
|
Basal Ganglia Diseases | 1 | 2005 | 149 | 0.060 |
Why?
|
Proportional Hazards Models | 5 | 2014 | 12354 | 0.060 |
Why?
|
Sex Distribution | 4 | 2006 | 2297 | 0.060 |
Why?
|
Nurse Practitioners | 1 | 2008 | 270 | 0.060 |
Why?
|
Respiration | 1 | 2011 | 1653 | 0.060 |
Why?
|
Breast | 1 | 2014 | 1969 | 0.060 |
Why?
|
Drug Resistance, Microbial | 1 | 2008 | 862 | 0.060 |
Why?
|
Peptic Ulcer | 2 | 2003 | 223 | 0.060 |
Why?
|
Antiparkinson Agents | 1 | 2005 | 184 | 0.060 |
Why?
|
Morbidity | 1 | 2010 | 1769 | 0.060 |
Why?
|
Video Games | 1 | 2006 | 184 | 0.060 |
Why?
|
Demography | 2 | 2006 | 1656 | 0.060 |
Why?
|
Fever | 1 | 2011 | 1616 | 0.060 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2006 | 320 | 0.060 |
Why?
|
Research | 1 | 1992 | 1999 | 0.060 |
Why?
|
Urban Health Services | 1 | 2005 | 179 | 0.060 |
Why?
|
CD4 Lymphocyte Count | 1 | 2010 | 2559 | 0.060 |
Why?
|
Gastric Acid | 1 | 2003 | 104 | 0.060 |
Why?
|
Half-Life | 1 | 2004 | 661 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5510 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 1518 | 0.060 |
Why?
|
Formularies as Topic | 3 | 1999 | 91 | 0.060 |
Why?
|
Diabetic Nephropathies | 1 | 2010 | 984 | 0.050 |
Why?
|
Population Surveillance | 2 | 2003 | 2616 | 0.050 |
Why?
|
Common Cold | 1 | 2003 | 61 | 0.050 |
Why?
|
Medical Records Systems, Computerized | 1 | 2009 | 1205 | 0.050 |
Why?
|
Patient Participation | 2 | 2010 | 1457 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2011 | 6538 | 0.050 |
Why?
|
Boston | 4 | 2004 | 9313 | 0.050 |
Why?
|
Drug Administration Schedule | 3 | 2010 | 4933 | 0.050 |
Why?
|
Albuterol | 1 | 2023 | 208 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2018 | 3445 | 0.050 |
Why?
|
Fluid Therapy | 2 | 1996 | 593 | 0.050 |
Why?
|
Cephalothin | 1 | 2001 | 36 | 0.050 |
Why?
|
Probability | 2 | 2008 | 2505 | 0.050 |
Why?
|
Penicillin G | 1 | 2001 | 42 | 0.050 |
Why?
|
Insurance, Medigap | 1 | 2001 | 19 | 0.050 |
Why?
|
Reminder Systems | 2 | 2008 | 371 | 0.050 |
Why?
|
Disease Management | 3 | 2012 | 2459 | 0.050 |
Why?
|
Ampicillin | 1 | 2001 | 139 | 0.050 |
Why?
|
Health Plan Implementation | 2 | 2020 | 352 | 0.050 |
Why?
|
Community Health Centers | 1 | 2005 | 430 | 0.050 |
Why?
|
Time | 1 | 2003 | 542 | 0.050 |
Why?
|
Mental Health Services | 2 | 2008 | 1643 | 0.050 |
Why?
|
Asia | 2 | 2013 | 610 | 0.050 |
Why?
|
Infant Care | 1 | 2002 | 183 | 0.050 |
Why?
|
User-Computer Interface | 1 | 2008 | 1431 | 0.050 |
Why?
|
Patient Care Planning | 1 | 2007 | 921 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2010 | 1373 | 0.050 |
Why?
|
Diabetic Retinopathy | 1 | 2010 | 1210 | 0.050 |
Why?
|
Qualitative Research | 2 | 2020 | 2682 | 0.050 |
Why?
|
Kazakhstan | 1 | 2020 | 14 | 0.050 |
Why?
|
Hawaii | 1 | 2020 | 105 | 0.050 |
Why?
|
Child Behavior | 1 | 2006 | 839 | 0.050 |
Why?
|
Gentamicins | 1 | 2001 | 255 | 0.050 |
Why?
|
Cataract | 2 | 1986 | 834 | 0.050 |
Why?
|
Cephalosporins | 1 | 2001 | 204 | 0.050 |
Why?
|
Phototherapy | 1 | 2004 | 377 | 0.050 |
Why?
|
Medicare Part B | 1 | 2001 | 108 | 0.050 |
Why?
|
Etretinate | 1 | 2000 | 6 | 0.050 |
Why?
|
Postal Service | 1 | 2020 | 96 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 35421 | 0.050 |
Why?
|
Total Quality Management | 1 | 2001 | 274 | 0.050 |
Why?
|
Keratolytic Agents | 1 | 2000 | 31 | 0.050 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2003 | 347 | 0.050 |
Why?
|
Proton Pump Inhibitors | 1 | 2005 | 526 | 0.040 |
Why?
|
Body Weight | 2 | 2008 | 4669 | 0.040 |
Why?
|
Medical Records | 2 | 2010 | 1413 | 0.040 |
Why?
|
Depression | 3 | 2015 | 7766 | 0.040 |
Why?
|
Glaucoma | 1 | 1989 | 1159 | 0.040 |
Why?
|
Journalism, Medical | 1 | 2000 | 74 | 0.040 |
Why?
|
Weight Gain | 1 | 2010 | 2292 | 0.040 |
Why?
|
Eating | 1 | 2006 | 1536 | 0.040 |
Why?
|
Cameroon | 2 | 1996 | 71 | 0.040 |
Why?
|
Community-Acquired Infections | 1 | 2003 | 465 | 0.040 |
Why?
|
Dihydropyridines | 1 | 1999 | 67 | 0.040 |
Why?
|
Health Planning | 1 | 2001 | 238 | 0.040 |
Why?
|
Minnesota | 1 | 1999 | 344 | 0.040 |
Why?
|
Economics, Pharmaceutical | 2 | 2014 | 87 | 0.040 |
Why?
|
Activities of Daily Living | 2 | 2015 | 2418 | 0.040 |
Why?
|
Ethanol | 1 | 2005 | 1342 | 0.040 |
Why?
|
Gastroesophageal Reflux | 2 | 2003 | 782 | 0.040 |
Why?
|
Insurance Carriers | 1 | 2020 | 157 | 0.040 |
Why?
|
Communicable Disease Control | 1 | 2005 | 857 | 0.040 |
Why?
|
United States Food and Drug Administration | 3 | 2015 | 1584 | 0.040 |
Why?
|
Milk, Human | 1 | 2003 | 490 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2000 | 528 | 0.040 |
Why?
|
Computer Communication Networks | 1 | 2000 | 295 | 0.040 |
Why?
|
Government Programs | 1 | 2020 | 275 | 0.040 |
Why?
|
Maternal Health Services | 1 | 2003 | 455 | 0.040 |
Why?
|
Reference Values | 2 | 2019 | 4982 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2019 | 15295 | 0.040 |
Why?
|
Atrial Fibrillation | 2 | 2006 | 5034 | 0.040 |
Why?
|
Prognosis | 2 | 2011 | 29063 | 0.040 |
Why?
|
Cost-Benefit Analysis | 4 | 2010 | 5391 | 0.040 |
Why?
|
Survival Rate | 1 | 2011 | 12788 | 0.040 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 1998 | 204 | 0.040 |
Why?
|
Family | 2 | 2021 | 3147 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 3479 | 0.040 |
Why?
|
Diarrhea, Infantile | 1 | 1996 | 109 | 0.040 |
Why?
|
Heart Failure | 2 | 2017 | 10900 | 0.040 |
Why?
|
Professional Practice | 2 | 2009 | 326 | 0.030 |
Why?
|
Economic Competition | 1 | 2018 | 214 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2001 | 639 | 0.030 |
Why?
|
Aspirin | 3 | 2000 | 3282 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2001 | 1677 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2007 | 2576 | 0.030 |
Why?
|
Peer Review, Research | 1 | 2019 | 329 | 0.030 |
Why?
|
Postoperative Period | 1 | 2021 | 1842 | 0.030 |
Why?
|
Calcium Channel Blockers | 1 | 1999 | 690 | 0.030 |
Why?
|
Housing | 1 | 2000 | 664 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2007 | 10943 | 0.030 |
Why?
|
Vitamin A Deficiency | 1 | 1996 | 101 | 0.030 |
Why?
|
Attitude to Health | 4 | 2007 | 2052 | 0.030 |
Why?
|
Trachoma | 1 | 1995 | 29 | 0.030 |
Why?
|
Emergency Treatment | 1 | 1999 | 517 | 0.030 |
Why?
|
Losartan | 1 | 2017 | 299 | 0.030 |
Why?
|
Self Report | 2 | 2019 | 3558 | 0.030 |
Why?
|
Patient Simulation | 1 | 1997 | 309 | 0.030 |
Why?
|
Cardiovascular Agents | 1 | 2001 | 850 | 0.030 |
Why?
|
Portugal | 1 | 2014 | 87 | 0.030 |
Why?
|
Psychiatry | 1 | 2007 | 1695 | 0.030 |
Why?
|
Risk Assessment | 4 | 2019 | 23338 | 0.030 |
Why?
|
Rural Population | 3 | 1996 | 2210 | 0.030 |
Why?
|
Child Day Care Centers | 2 | 2005 | 123 | 0.030 |
Why?
|
Mood Disorders | 1 | 2020 | 1106 | 0.030 |
Why?
|
Pacific Islands | 1 | 2013 | 50 | 0.030 |
Why?
|
Vision, Low | 1 | 1996 | 168 | 0.030 |
Why?
|
Focus Groups | 1 | 2018 | 1321 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 1999 | 1240 | 0.030 |
Why?
|
Databases as Topic | 2 | 2009 | 475 | 0.030 |
Why?
|
Hospitals, Pediatric | 1 | 2002 | 1775 | 0.030 |
Why?
|
Incidence | 4 | 2008 | 20947 | 0.030 |
Why?
|
Nervous System Diseases | 1 | 2004 | 1622 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2016 | 1150 | 0.030 |
Why?
|
Finland | 1 | 2014 | 602 | 0.030 |
Why?
|
Decision Making | 2 | 2007 | 3887 | 0.030 |
Why?
|
Cesarean Section | 1 | 2001 | 1365 | 0.030 |
Why?
|
Vitamin A | 1 | 1996 | 615 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 2017 | 759 | 0.030 |
Why?
|
Homes for the Aged | 2 | 1992 | 260 | 0.030 |
Why?
|
Thrombolytic Therapy | 1 | 2002 | 2161 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1996 | 1572 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2014 | 5078 | 0.030 |
Why?
|
Surgical Wound Infection | 1 | 2001 | 1540 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 6489 | 0.020 |
Why?
|
Liver Diseases | 1 | 2000 | 1253 | 0.020 |
Why?
|
Incidental Findings | 1 | 2016 | 689 | 0.020 |
Why?
|
Narcotic Antagonists | 1 | 2015 | 562 | 0.020 |
Why?
|
Primary Prevention | 1 | 2018 | 1167 | 0.020 |
Why?
|
Pharmacopoeias as Topic | 1 | 2010 | 17 | 0.020 |
Why?
|
Equipment Design | 1 | 2019 | 3582 | 0.020 |
Why?
|
Survival Analysis | 3 | 2016 | 10252 | 0.020 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2011 | 199 | 0.020 |
Why?
|
State Government | 1 | 2013 | 372 | 0.020 |
Why?
|
HIV-1 | 1 | 2008 | 6939 | 0.020 |
Why?
|
Genes, BRCA2 | 1 | 2014 | 618 | 0.020 |
Why?
|
Hypercholesterolemia | 1 | 2017 | 1151 | 0.020 |
Why?
|
Behavior Therapy | 1 | 1996 | 865 | 0.020 |
Why?
|
Consumer Health Information | 1 | 2013 | 211 | 0.020 |
Why?
|
Mexico | 1 | 2012 | 690 | 0.020 |
Why?
|
West Indies | 1 | 1989 | 34 | 0.020 |
Why?
|
Reoperation | 1 | 2019 | 4201 | 0.020 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 781 | 0.020 |
Why?
|
Motivation | 2 | 1996 | 1971 | 0.020 |
Why?
|
Urban Health | 2 | 1996 | 547 | 0.020 |
Why?
|
Fibrinolytic Agents | 1 | 1999 | 2158 | 0.020 |
Why?
|
Long-Term Care | 1 | 2013 | 607 | 0.020 |
Why?
|
Pharmacy Service, Hospital | 1 | 2010 | 133 | 0.020 |
Why?
|
Uremia | 1 | 1990 | 201 | 0.020 |
Why?
|
Administrative Personnel | 1 | 2010 | 187 | 0.020 |
Why?
|
Drugs, Chinese Herbal | 1 | 2010 | 144 | 0.020 |
Why?
|
Drug Substitution | 1 | 2011 | 281 | 0.020 |
Why?
|
Environment | 1 | 1995 | 1124 | 0.020 |
Why?
|
Rural Health | 2 | 1996 | 305 | 0.020 |
Why?
|
Databases, Bibliographic | 1 | 2008 | 128 | 0.020 |
Why?
|
Energy Intake | 1 | 1996 | 2148 | 0.020 |
Why?
|
Pharmacists | 1 | 2010 | 248 | 0.020 |
Why?
|
Africa South of the Sahara | 1 | 2010 | 724 | 0.020 |
Why?
|
Buprenorphine | 1 | 2015 | 640 | 0.020 |
Why?
|
Enema | 1 | 2008 | 141 | 0.020 |
Why?
|
Sigmoidoscopy | 1 | 2008 | 156 | 0.020 |
Why?
|
Europe | 1 | 2014 | 3339 | 0.020 |
Why?
|
Comprehension | 1 | 2013 | 610 | 0.020 |
Why?
|
Blood Pressure Determination | 1 | 2011 | 634 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 681 | 0.020 |
Why?
|
Hydrocodone | 1 | 2006 | 47 | 0.020 |
Why?
|
Blood Transfusion | 1 | 1993 | 1301 | 0.020 |
Why?
|
Palliative Care | 1 | 2022 | 3493 | 0.020 |
Why?
|
Coronary Disease | 1 | 2001 | 6077 | 0.020 |
Why?
|
Exercise | 1 | 2023 | 5615 | 0.020 |
Why?
|
Child Welfare | 1 | 2010 | 523 | 0.020 |
Why?
|
Blood Coagulation | 1 | 1992 | 1127 | 0.020 |
Why?
|
Electrocardiography | 1 | 1999 | 6442 | 0.020 |
Why?
|
Saudi Arabia | 1 | 1986 | 209 | 0.020 |
Why?
|
Automation | 1 | 2008 | 584 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 4851 | 0.020 |
Why?
|
Chlorpromazine | 1 | 2005 | 111 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 1990 | 725 | 0.020 |
Why?
|
Epidemiologic Methods | 2 | 2006 | 1364 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2008 | 511 | 0.020 |
Why?
|
Alcohols | 1 | 2005 | 92 | 0.020 |
Why?
|
Mortality | 1 | 2016 | 2864 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2008 | 968 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3508 | 0.020 |
Why?
|
Dopamine Antagonists | 1 | 2005 | 296 | 0.020 |
Why?
|
Methadone | 1 | 2006 | 306 | 0.020 |
Why?
|
Obesity | 1 | 2006 | 12745 | 0.010 |
Why?
|
Evidence-Based Medicine | 2 | 2008 | 3610 | 0.010 |
Why?
|
Gels | 1 | 2005 | 427 | 0.010 |
Why?
|
Recurrence | 1 | 2015 | 8340 | 0.010 |
Why?
|
Haloperidol | 1 | 2005 | 397 | 0.010 |
Why?
|
Restaurants | 1 | 2006 | 236 | 0.010 |
Why?
|
Hospitals, Teaching | 2 | 2002 | 1179 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2022 | 9239 | 0.010 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2006 | 245 | 0.010 |
Why?
|
Drug Synergism | 1 | 2008 | 1792 | 0.010 |
Why?
|
Physician-Patient Relations | 2 | 2008 | 3229 | 0.010 |
Why?
|
Speech | 1 | 2008 | 540 | 0.010 |
Why?
|
Life Style | 1 | 1995 | 3835 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1344 | 0.010 |
Why?
|
Infant Food | 1 | 2003 | 141 | 0.010 |
Why?
|
Laparoscopy | 1 | 2015 | 2151 | 0.010 |
Why?
|
Specialization | 1 | 2008 | 777 | 0.010 |
Why?
|
Risperidone | 1 | 2005 | 383 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2015 | 2245 | 0.010 |
Why?
|
Communication | 1 | 1996 | 3749 | 0.010 |
Why?
|
Mental Recall | 1 | 2008 | 1205 | 0.010 |
Why?
|
Morphine | 1 | 2006 | 657 | 0.010 |
Why?
|
Eye Diseases | 2 | 1990 | 669 | 0.010 |
Why?
|
Internal Medicine | 1 | 2009 | 1009 | 0.010 |
Why?
|
Endometritis | 1 | 2001 | 48 | 0.010 |
Why?
|
Hospitals, Voluntary | 1 | 2001 | 40 | 0.010 |
Why?
|
Interprofessional Relations | 1 | 2008 | 1011 | 0.010 |
Why?
|
Perception | 1 | 2008 | 1198 | 0.010 |
Why?
|
Colombia | 1 | 2001 | 258 | 0.010 |
Why?
|
Fruit | 1 | 2006 | 1142 | 0.010 |
Why?
|
Opioid-Related Disorders | 1 | 2015 | 2065 | 0.010 |
Why?
|
Vegetables | 1 | 2006 | 1182 | 0.010 |
Why?
|
Body Height | 1 | 2006 | 1577 | 0.010 |
Why?
|
Decision Support Systems, Clinical | 1 | 2009 | 1164 | 0.010 |
Why?
|
Community Networks | 1 | 2001 | 203 | 0.010 |
Why?
|
Medicine | 1 | 2008 | 946 | 0.010 |
Why?
|
Geriatric Assessment | 1 | 2007 | 1372 | 0.010 |
Why?
|
Thromboembolism | 1 | 2006 | 986 | 0.010 |
Why?
|
Nicardipine | 1 | 1999 | 60 | 0.010 |
Why?
|
Alendronate | 1 | 2000 | 171 | 0.010 |
Why?
|
Vision Disorders | 1 | 1986 | 1058 | 0.010 |
Why?
|
Diltiazem | 1 | 1999 | 133 | 0.010 |
Why?
|
Nifedipine | 1 | 1999 | 226 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17446 | 0.010 |
Why?
|
Verapamil | 1 | 1999 | 244 | 0.010 |
Why?
|
Hospital Mortality | 2 | 2002 | 5317 | 0.010 |
Why?
|
Pravastatin | 1 | 2000 | 395 | 0.010 |
Why?
|
Diet | 1 | 1996 | 7939 | 0.010 |
Why?
|
Ethics | 1 | 1997 | 94 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2009 | 1917 | 0.010 |
Why?
|
Visual Acuity | 1 | 1986 | 2530 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2001 | 675 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2006 | 2356 | 0.010 |
Why?
|
Home Care Services | 1 | 2002 | 606 | 0.010 |
Why?
|
Selection Bias | 1 | 1998 | 371 | 0.010 |
Why?
|
Drug Information Services | 1 | 1996 | 51 | 0.010 |
Why?
|
Persuasive Communication | 1 | 1996 | 59 | 0.010 |
Why?
|
Animals | 2 | 2018 | 168757 | 0.010 |
Why?
|
Mutation | 1 | 2020 | 29786 | 0.010 |
Why?
|
Conflict of Interest | 1 | 2000 | 544 | 0.010 |
Why?
|
Blood Pressure | 1 | 2011 | 8554 | 0.010 |
Why?
|
Family Planning Services | 1 | 1997 | 263 | 0.010 |
Why?
|
Patient Advocacy | 1 | 1997 | 353 | 0.010 |
Why?
|
Disclosure | 1 | 2000 | 736 | 0.010 |
Why?
|
Perioperative Care | 1 | 2001 | 1002 | 0.010 |
Why?
|
Hemorrhage | 1 | 2006 | 3461 | 0.010 |
Why?
|
Quality of Life | 1 | 1995 | 12804 | 0.010 |
Why?
|
Stroke | 2 | 2006 | 9981 | 0.010 |
Why?
|
Inservice Training | 1 | 1996 | 392 | 0.010 |
Why?
|
Aging | 1 | 1992 | 8664 | 0.010 |
Why?
|
Anticholesteremic Agents | 1 | 2000 | 979 | 0.010 |
Why?
|
Cost Savings | 1 | 1998 | 926 | 0.010 |
Why?
|
Consumer Organizations | 1 | 1992 | 10 | 0.010 |
Why?
|
Education, Nursing, Continuing | 1 | 1992 | 75 | 0.010 |
Why?
|
Prothrombin Time | 1 | 1992 | 119 | 0.010 |
Why?
|
Geriatric Psychiatry | 1 | 1992 | 70 | 0.010 |
Why?
|
Education, Continuing | 1 | 1992 | 112 | 0.010 |
Why?
|
Hospitals, Community | 1 | 1993 | 348 | 0.010 |
Why?
|
Mental Processes | 1 | 1992 | 249 | 0.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3255 | 0.010 |
Why?
|
Osteoporosis | 1 | 2000 | 1580 | 0.010 |
Why?
|
Blood Urea Nitrogen | 1 | 1990 | 191 | 0.010 |
Why?
|
Politics | 1 | 1997 | 791 | 0.010 |
Why?
|
Institutionalization | 1 | 1990 | 104 | 0.010 |
Why?
|
Patient Selection | 1 | 2002 | 4215 | 0.010 |
Why?
|
Electrolytes | 1 | 1990 | 282 | 0.010 |
Why?
|
Parents | 1 | 2002 | 3407 | 0.010 |
Why?
|
Urban Population | 1 | 1996 | 2021 | 0.000 |
Why?
|
Drug Interactions | 1 | 1992 | 1460 | 0.000 |
Why?
|
Algorithms | 1 | 2008 | 13881 | 0.000 |
Why?
|
Risk | 1 | 1999 | 9687 | 0.000 |
Why?
|
Biomedical Research | 1 | 2000 | 3309 | 0.000 |
Why?
|
Forecasting | 1 | 1993 | 2951 | 0.000 |
Why?
|
Prospective Studies | 2 | 2003 | 53288 | 0.000 |
Why?
|
Surgical Procedures, Operative | 1 | 1993 | 1876 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1990 | 6365 | 0.000 |
Why?
|